Search results
Results from the WOW.Com Content Network
Takeda has also gotten more aggressive about upskilling employees. More than half of the company’s workforce has taken virtual or in-person courses and training for new technologies, like AI.
A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year. Takeda Pharmaceutical Co Ltd plans to ...
Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. [12] One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It ...
The first products TAP file new drug applications for, were two cephalosporins, cefmenoxime (Cefmax) and cefsulodin (Cefonomil), estazolam for sleep disorders, and leuprorelin; leuprorelin was the first one approved, in 1985. [3] In 1998 Takeda established its own US R&D and sales force, for the diabetes drug pioglitazone (Actos). [1]
Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical. Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product ...
Prior to Frazier Healthcare Partners, Yamada was executive vice-president and a board member of Takeda Pharmaceuticals, and served as the chief medical and scientific officer of the company. Before joining Takeda, Yamada was the president of the global health program at the Bill & Melinda Gates Foundation. In this capacity he oversaw grants ...
Brazil's top public prosecutor is not likely to issue any indictments until next year for former President Jair Bolsonaro, members of his government and military officers who allegedly planned a ...
Soticlestat (TAK-935, OV-935) is an experimental anticonvulsant and cholesterol 24-hydroxylase inhibitor being investigated as a treatment for Dravet syndrome, Lennox–Gastaut syndrome, tuberous sclerosis complex, dup15q syndrome, and CDKL5 deficiency disorder.